Literature DB >> 10052947

Biochemical and physical properties of remnant-HDL2 and of pre beta 1-HDL produced by hepatic lipase.

K Guendouzi1, B Jaspard, R Barbaras, C Motta, C Vieu, Y Marcel, H Chap, B Perret, X Collet.   

Abstract

The hepatic lipase acting on triglyceride-rich high-density lipoprotein2 (HDL2) induces the formation of pre beta 1-HDL, leaving a residual alpha-migrating HDL particle that was named "remnant-HDL2" (Barrans, A., Collet, X., Barbaras, R., Jaspard, B., Manent, J., Vieu, C., Chap, H., and Perret, B. (1994) J. Biol. Chem. 269, 11572-11577.]. In this study, these two product particles generated by hepatic lipase were isolated by density gradient ultracentrifugation. Particles were first characterized in terms of chemical composition, density, and mass. The pre beta 1-HDL obtained in vitro contain one to two molecules of apoA-I, associated with phospholipids, and free and esterified cholesterol. When compared to triglyceride-rich HDL2, remnant-HDL2 have lost on average one molecule of apoA-I, 60% of triacylglycerols, and 15% of phospholipids. The estimated composition is concordant with the hypothesis of the splitting of a substrate particle into one pre beta 1-HDL and one remnant-HDL2. Spectroscopic studies were carried out to monitor changes in lipid fluidity upon lipolysis. The fluorescence anisotropy was measured using (1,6)-diphenyl-hexa-(1,3, 5)-triene as a probe, and the degree of order was calculated from electron spin resonance spectra using the 5-nitroxy-derivative of stearic acid. Both approaches showed a decreased lipid fluidity in remnant-HDL2, as compared to triglyceride-rich HDL2. The immunoreactivity of apoA-I toward several monoclonal antibodies was assayed as a reflection of changes of apoA-I conformation. In remnant-HDL2, as compared to triglyceride-rich HDL2, a lower reactivity was noted with the 2G11 antibody, which interacts in the NH2 terminal part of apoA-I. Finally, remnant-HDL2 was clearly different from HDL3 with respect to all of the parameters studied, demonstrating that hepatic lipase does not promote the direct conversion of HDL2 to HDL3. Thus, hepatic lipase produces remnant-HDL2 particles, which display modifications of apoA-I conformation and of fluidity of the lipid environment. This newly described HDL2 subfraction may play a major role in the reverse cholesterol transport.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10052947     DOI: 10.1021/bi9815086

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  7 in total

1.  Key questions resulting from the JUPITER trial assessing cardiovascular disease intervention with rosuvastatin.

Authors:  Shirya Rashid
Journal:  World J Cardiol       Date:  2009-12-31

2.  Putting cholesterol in its place: apoE and reverse cholesterol transport.

Authors:  Robert W Mahley; Yadong Huang; Karl H Weisgraber
Journal:  J Clin Invest       Date:  2006-05       Impact factor: 14.808

3.  Evidence for the presence of lipid-free monomolecular apolipoprotein A-1 in plasma.

Authors:  Osamu Miyazaki; Jun Ogihara; Isamu Fukamachi; Takafumi Kasumi
Journal:  J Lipid Res       Date:  2013-12-04       Impact factor: 5.922

Review 4.  Fat depots, free fatty acids, and dyslipidemia.

Authors:  Jon O Ebbert; Michael D Jensen
Journal:  Nutrients       Date:  2013-02-07       Impact factor: 5.717

Review 5.  New insights into the mechanism of low high-density lipoprotein cholesterol in obesity.

Authors:  Hao Wang; Dao-Quan Peng
Journal:  Lipids Health Dis       Date:  2011-10-12       Impact factor: 3.876

6.  Subcutaneous Adipocyte Lipolysis Contributes to Circulating Lipid Levels.

Authors:  Mikael Rydén; Peter Arner
Journal:  Arterioscler Thromb Vasc Biol       Date:  2017-06-29       Impact factor: 8.311

Review 7.  Obesity and its metabolic complications: the role of adipokines and the relationship between obesity, inflammation, insulin resistance, dyslipidemia and nonalcoholic fatty liver disease.

Authors:  Un Ju Jung; Myung-Sook Choi
Journal:  Int J Mol Sci       Date:  2014-04-11       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.